Phaseline

Companies › Jiangsu Renocell Biotech Company

Jiangsu Renocell Biotech Company: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RY_SW01 cell injection
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) with immunomodulatory and tissue-r
–Phase 2Lupus Nephritis; Systemic SclerosisDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06058078RY_SW01 cell injectionPhase 2Lupus NephritisImmunologyDec 2028
NCT06058091RY_SW01 cell injectionPhase 1Systemic SclerosisImmunologyDec 2035

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cynata Therapeutics Wuxi Cellular Biopharmaceutical Group Artiva Biotherapeutics Kyverna Therapeutics Apogee Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.